Key Highlights

  • Third-quarter 2026 net loss was USD 30.9 million, or USD 0.85 per share.
  • Research and development expenses were USD 24.6 million, against USD 19.6 million a year earlier.
  • Cash and cash equivalents were USD 47.6 million, with short-term investments of USD 121.1 million.
  • The company completed its EVO756 Phase 2b trial in chronic spontaneous urticaria in October.

Evommune (NYSE:EVMN) reported a third-quarter 2026 net loss of USD 30.9 million, or USD 0.85 per share, against an estimate of a loss of USD 0.83 per share. The Palo Alto, California-based company is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. It reported no Revenue for the quarter.

The company recorded license revenue of USD 10.0 million in the third quarter of 2025, which it did not repeat in the current period. The filing also lists two events after the quarter end, a development milestone under its Maruho agreement and a new license agreement with Hinova Pharmaceuticals.

Operating Results

Research and development expenses were USD 24,551 thousand for the three months ended September 30, 2026, against USD 19,639 thousand. The filing says the increase of USD 4.9 million was primarily due to higher preclinical research expenses for undisclosed discovery programs and personnel costs, partially offset by lower clinical trial expenses for EVO756. General and administrative expenses were USD 8,775 thousand, against USD 3,689 thousand.

Total operating expenses were USD 33,326 thousand, against USD 23,328 thousand, and loss from operations was USD 33,326 thousand, against USD 13,328 thousand. Interest income was USD 2,479 thousand, against USD 862 thousand, and total other income, net, was USD 2,449 thousand, against USD 853 thousand.

Net loss was USD 30,877 thousand, against USD 12,475 thousand, or USD 0.85 per basic and diluted share, against USD 8.07. Weighted average shares were 36,326,051, against 1,545,010. For the nine months, net loss was USD 84,797 thousand, or USD 2.40 per share, against USD 40,597 thousand, or USD 26.36.

Cash, Investments and Financing

At September 30, 2026, cash and cash equivalents were USD 47,570 thousand, short-term investments were USD 121,068 thousand and Long-Term Investments were USD 93,612 thousand. Total Assets were USD 278,298 thousand and total stockholders' Equity was USD 251,368 thousand, against USD 224,946 thousand and USD 205,566 thousand at December 31, 2025. The accumulated Deficit was USD 305.9 million.

Net cash provided by financing activities for the nine months was USD 117.7 million. It included net proceeds of USD 117.1 million from a February 2026 private Placement of 4,494,279 shares at USD 27.88 per share, and USD 1.0 million from stock option exercises. Management states that existing cash, cash equivalents and investments are sufficient to fund the current operating plan for at least twelve months from the issuance date of the financial statements.

Milestones and Licensing After Quarter End

In October 2026, the company completed its Phase 2b clinical trial of EVO756 in chronic spontaneous urticaria, including the final clinical study report. The filing says this triggered a USD 5.0 million development milestone payment under the Maruho Greater Asia Agreement, which is recognized as revenue in the fourth quarter of 2026.

In November 2026, the company entered into a license agreement with Hinova Pharmaceuticals under which it holds an exclusive license to develop and commercialize EVO570, an oral VAV1 molecular glue degrader, and related compounds worldwide, excluding mainland China, Hong Kong, Macau and Taiwan. The company agreed to make an upfront payment of USD 20.0 million in cash and issue pre-funded warrants to purchase up to 1,262,413 shares of common stock. It may also owe milestone payments of up to USD 1.1 billion tied to development, regulatory and commercial milestones, plus tiered royalties from the mid single digits to the low double digits on future sales. The company said it is still evaluating the accounting impact of the transaction.